Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study

被引：0
|
作者：
Baldacci, Simon [1 ]
Mazieres, Julien [2 ]
Tomasini, Pascale [3 ]
Girard, Nicolas [4 ]
Guisier, Florian [5 ]
Valette, Clarisse Audigier [6 ]
Monnet, Isabelle [7 ]
Wislez, Marie [8 ]
Perol, Maurice [9 ]
Do, Pascal [10 ]
Dansin, Eric [11 ]
Leduc, Charlotte [12 ]
Leprieur, Etienne Giroux [13 ]
Moro-Sibilot, Denis [14 ]
Kherrouche, Zoulika [15 ]
Labreuche, Julien [16 ]
Cortot, Alexis [1 ]
机构：
[1] Univ Lille, CHU Lille, Serv Pneumol & Oncol Thorac, Lille, France
[2] Toulouse Univ Hosp, Toulouse, France
[3] AP HM, Dept Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[4] Hosp Civils Lyon, Louis Pradel Hosp, Resp Med, Lyon, France
[5] Rouen Univ Hosp, Rouen, France
[6] Ctr Hosp St Musse, Toulon, France
[7] Ctr Hosp Intercommunal Creteil, Creteil, France
[8] Hop Tenon, Serv Pneumol, AP HP, Paris, France
[9] Ctr Leon Berard, Grp Thorac & Orl, Lyon, France
[10] Ctr Reg Lutte Contre Le Canc Francois Baclesse, Caen, France
[11] Ctr Oscar Lambret, Lille, France
[12] CHU Strasbourg, Strasbourg, France
[13] Hop Ambroise Pare, AP HP, Boulogne, France
[14] Pole Thorax & Vaisseaux, Unite Oncol Thorac, Serv Pneumol, Grenoble, France
[15] Univ Lille, CNRS, Inst Pasteur Lille, Inst Biol Lille,Umr 8161, Lille, France
[16] Univ Lille, Ea 2694, Lille, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
MET amplification; non-small cell lung cancer; EGFR mutation; TKI resistance;
D O I：
10.1016/j.jtho.2016.11.1718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-051
引用
收藏
页码：S1219 / S1220
页数：2
相关论文
共 50 条
  • [1] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Audigier-Valette, Clarisse
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Tulasne, David
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis B.
    ONCOTARGET, 2017, 8 (62) : 105103 - 105114
  • [2] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [3] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [4] Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
    Novak, Jennifer
    Salgia, Ravi
    West, Howard
    Villalona-Calero, Miguel A.
    Sampath, Sagus
    Williams, Terence
    Villaflor, Victoria
    Massarelli, Erminia
    Pathak, Ranjan
    Koczywas, Marianna
    Chau, Brittney
    Amini, Arya
    CANCERS, 2022, 14 (16)
  • [5] Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
    Li, W.
    Che, G.
    Zhao, J.
    Zhao, Y.
    Duan, J.
    Zhou, C.
    Zhao, X.
    Wu, L.
    Zhang, Y.
    Zhou, C.
    Zhou, C.
    Zhou, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S105 - S106
  • [6] Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
    Urbanska, Edyta M.
    Grauslund, Morten
    Koffeldt, Peter R.
    Truelsen, Sarah L. B.
    Loefgren, Johan O.
    Costa, Junia C.
    Melchior, Linea C.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [7] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [8] Nationwide real-world overall survival in advanced EGFR mutated NSCLC using different TKI.
    Gijtenbeek, Rolof G. P.
    Damhuis, Ronald A. M.
    Van der Wekken, Anthonie J.
    Hendriks, Lizza E. L.
    Groen, Harry J. M.
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kei Kunimasa
    Kazumi Nishino
    Yoshiharu Sato
    Masahide Mori
    Shoichi Ihara
    Hidekazu Suzuki
    Izumi Nagatomo
    Toru Kumagai
    Toshitaka Morishima
    Fumio Imamura
    Scientific Reports, 12
  • [10] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kunimasa, Kei
    Nishino, Kazumi
    Sato, Yoshiharu
    Mori, Masahide
    Ihara, Shoichi
    Suzuki, Hidekazu
    Nagatomo, Izumi
    Kumagai, Toru
    Morishima, Toshitaka
    Imamura, Fumio
    SCIENTIFIC REPORTS, 2022, 12 (01)
12345